People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study

Novo Nordisk's Wegovy pill may give patients an exit ramp from weekly obesity injections. Real-world data the company presented Wednesday show that people who switched from injectable treatments to the oral Wegovy kept losing weight after three months.

The finding matters because it addresses a core question for the obesity franchise: whether patients must stay on weekly shots indefinitely or can move to a more convenient format without giving up results. Per the analysis, the switchers continued to lose weight rather than plateau or regain after the change in delivery method.

Interpretation, not stated in the data: if the pattern holds in larger and longer datasets, the pill could function as a maintenance or step-down option, which would broaden its addressable use beyond new patients. That would shape how investors model uptake of the oral product against Novo's injectable lineup. It would also raise questions about whether pill conversions cannibalize injection volumes, though the presented analysis does not quantify that.

The evidence comes from a three-month window, a short horizon for a chronic-weight-management therapy. Durability beyond that point remains the open variable, and real-world analyses lack the controls of randomized trials.